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Cerebrovascular disease is a leading cause of morbidity and mortality in developed countries around the world. In the United
States, there are an estimated 700,000 cases of stroke annually (of which over 85% are ischemic), costing an estimated $56.8
billion in associated treatment. Large vessel internal carotid artery stenosis is an important cause of ischemic stroke.
Population-based studies have shown that the prevalence of carotid stenosis is0.5% in the sixth decade of life and increases
to10% in the ninth decade. Themajority of patients are asymptomatic. Asymptomatic carotid stenosis with<75% lumen loss
carries a stroke risk of 1.3% annually, whereas the combined risk of myocardial ischemia and vascular death is as high as 10%.
With diameter stenosis>75%, the combined stroke and transient ischemic attack risk increases to11% annually, with 75% of
events ipsilateral to the affected artery. Other studies have also shown that the risk of stroke increases proportionately to the
severity of stenosis. The risk is higher for those patients who are symptomatic. In this review, wewill discuss antiplatelet agents
to prevent cerebrovascular events in the context of extracranial carotid artery disease. It is beyond the scope of this article to
discuss antiplatelet treatment for other etiologies of stroke. (J Vasc Surg 2009;50:431-9.)Cerebrovascular disease is a leading cause of morbidity
andmortality in developed countries around theworld. In the
United States, there are an estimated 700 000 cases of stroke
annually (of which over 85% are ischemic), costing an esti-
mated $56.8 billion in associated treatment.1 Large vessel
internal carotid artery stenosis is an important cause of isch-
emic stroke. Population-based studies have shown that the
prevalence of carotid stenosis is0.5% in the sixth decade of
life and increases to10% in theninthdecade.Themajority of
patients are asymptomatic.2-4 Asymptomatic carotid stenosis
with 75% lumen loss carries a stroke risk of 1.3% annually,
whereas the combined risk of myocardial ischemia and vascu-
lar death is as high as 10%.5With diameter stenosis75%, the
combined stroke and TIA risk increases to 11% annually,
with 75% of events ipsilateral to the affected artery. Other
studies have also shown that the risk of stroke increases pro-
portionately to the severity of stenosis.6,7
Currently, the decision to perform prophylactic carotid
endarterectomy (CEA) in asymptomatic patients is based
mainly on the presence of a hemodynamically significant
60% to 99% internal carotid artery stenosis in relation to the
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doi:10.1016/j.jvs.2009.04.052normal lumen of the distal internal carotid artery. Com-
pared with best medical treatment alone, this strategy re-
duces the risk of ipsilateral stroke, as shown by the Veterans
Administration (VA) study, the Asymptomatic Carotid
Atherosclerosis Study (ACAS), and the Asymptomatic Ca-
rotid Surgery Trial (ACST).8-10 The midterm overall risk
reduction is minimal, however; the ACAS trial reported
that in patients with stenosis 60%, CEA reduced the
annual risk of stroke from 2% to 1%, which implies that
approximately 20 procedures need to be performed to
prevent one stroke in five years. Recently, Nicolaides and
colleagues reported on 462 asymptomatic patients with
60% to 99% carotid artery stenosis. The cumulative event-
free rate at eight years was 0.81 (2.4% annual event rate) in
the absence of silent cerebral embolic infarcts and 0.63
(4.6% annual event rate) in the 86 patients where they were
present (log-rank P  .032).11 The risk is higher for those
patients who are symptomatic. In this review, we will
discuss antiplatelet agents to prevent cerebrovascular events
in the context of extracranial carotid artery disease. It is
beyond the scope of this article to discuss antiplatelet
treatment for other etiologies of stroke outside the diagno-
sis of significant carotid stenosis.
ROLE OF ANTIPLATELET THERAPY IN
PRIMARY PREVENTION OF STROKE
Prevention of a first stroke is the critical strategy to
reduce morbidity and mortality associated with cerebrovas-
cular disease. Primary preventive measures are influenced
by the patient’s risk factor profile and control of these risks.
There has been compelling evidence for more than 30 years
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prevention of stroke as well as to the prevention or reduc-
tion of other target-organ damage, including congestive
heart failure and renal failure.12 A meta-analysis of 18
long-term randomized trials found that both -blocker
therapy and treatment with diuretics were effective in pre-
venting stroke.13 Overall, antihypertensive therapy is asso-
ciated with a 35% to 44% reduction in the incidence of
stroke.14 Likewise, statin therapy has been shown to pro-
duce consistent benefits in large randomized trials in de-
creasing stroke risk.15-20 The risk of stroke in diabetic
patients with hypertension is increased and blood pressure
and blood glucose levels should be controlled. Atrial fibril-
lation alone is associated with a 3- to 4-fold increased risk of
stroke after adjustment for other vascular risk factors.21 For
those without prior transient ischemic attack (TIA) or
stroke, 2% to 4% per year have an ischemic stroke.22,23
Randomized clinical trials have firmly established the value
of antithrombotic therapies for reducing the risk of stroke
in patients with atrial fibrillation. Risk is reduced by 60%
with adjusted-dose warfarin and by 20% with aspirin.24
Adjusted-dose warfarin reduces stroke by 45% as com-
pared with aspirin.23 Randomized trials have also been
conducted comparing a direct thrombin inhibitor to high-
quality adjusted-dose warfarin in persons with atrial fibril-
lation, but the U.S. Food and Drug Administration has not
approved its use.25,26
The use of aspirin in the primary prevention of major
cardiovascular events has been studied in key trials such as
the BritishDoctors’ Trial, the Physicians’ Health Study, the
Hypertension Optimal Treatment Study, the Thrombosis
Prevention Trial, the Primary Prevention Project, and the
Women’s Health Study.27-32 These studies comprised
close to 100,000 patients with the results consistently
supportive of aspirin as an effective primary preventive
agent. In fact, five of the six aforementioned primary pre-
vention trials recruited patients at low-risk for coronary
heart disease (CHD) (1% per year), and therefore, rela-
tively few major CVD outcome events were recorded dur-
ing these studies. Alternatively, aspirin efficacy has been
more consistently demonstrated in high-risk patients (eg,
those with a history of ischemic stroke, transient ischemic
attack, or myocardial infarction).
The efficacy of aspirin was proven in the Antithrom-
botic Trialists’ Collaboration, which studied a total of
200,000 patients enrolled in 287 studies. Two types of
studies were included in this meta-analysis: those involving
135,000 patients comparing antiplatelet therapy versus
control, and 77,000 patients comparing different antiplate-
let regimens.33 Overall, among these high risk patients,
antiplatelet therapy reduced the occurrence of any serious
vascular event by 25%; non-fatal myocardial infarction
was reduced by 30%, non-fatal stroke by 25%, and
vascular mortality by 15% (with no apparent adverse
effect on total mortality). Aspirin was the most widely
studied antiplatelet drug, with doses of 75-150 mg daily at
least as effective as higher daily doses. The effects of doses
lower than 75 mg daily were less efficacious. Clopidogrelreduced serious vascular events by 10% compared with
aspirin, which was similar to the 12% reduction observed
with ticlopidine. The addition of dipyridamole to aspirin
produced no significant further reduction in vascular events
compared with aspirin alone.
The Women’s Health Study randomized 39,876 ini-
tially asymptomatic women aged 45 years of age and older
to receive 100 mg of aspirin or placebo on alternate days.
Patients were followed for 10 years, with the primary
endpoint being a first major vascular event (nonfatal MI,
nonfatal stroke, or cardiovascular death).32 Unlike data
from prior studies that included mainly men, this study
found a nonsignificant 9% reduction (Relative Risk (RR)
0.91; 95% Confidence Interval (CI) 0.80 to 1.03; P .13)
in the combined primary end point among women, but a
statistically significant 17% reduction in the risk of stroke
(RR 0.83; 95%CI 0.69 to 0.99; P .04). This was based
on a 24% reduction in the risk of ischemic stroke and a
nonsignificant increase in the risk of hemorrhagic stroke.
The most consistent benefit for aspirin was in women 65
years of age at study entry, among whom the primary
endpoint was significant; risk of major cardiovascular events
was reduced by 26% (RR 0.74; 95% CI 0.59 to 0.92; P
.008), including a 30% reduction in the risk of ischemic
stroke.
The Physicians’ Health Study was a randomized, double-
blind, placebo-controlled trial designed to determine
whether low-dose aspirin (325 mg every other day) de-
creased cardiovascular mortality.28 Among 22,071 partici-
pants with a mean follow-up of 60.2 months, there was a
44% relative reduction in the risk of myocardial infarction
(RR  0.56; 95% CI 0.45 to 0.70; P  .00001) in the
aspirin group (254.8 per 100,000 per year as compared
with 439.7 in the placebo group). It is interesting to note
that there was a slightly increased risk of stroke among
those taking aspirin but this was not statistically significant.
This trend was observed primarily in the subgroup with
hemorrhagic stroke (RR 2.14; 95% CI 0.96 to 4.77; P
.06). As a result, however, this study did not advocate for
aspirin as a primary preventive strategy for stroke.
Recently, the U.S. Preventive Services Task Force
(USPSTF) published their updated recommendations for
the use of aspirin for the prevention of cardiovascular
disease statement.34 Having reviewed the available data
since 2002, especially the Women’s Health Study (WHS),
the USPSTF recommended the use of aspirin for women
age 55 to 79 years when the potential benefit of a reduction
in ischemic strokes outweighs the potential harm of an
increase in gastrointestinal hemorrhage (Class A recom-
mendation).
PRIMARY STROKE PREVENTION GUIDELINES
Current guideline statements recommend (Class I,
Level of Evidence A: Conditions for which there is evidence for
and/or general agreement that the procedure or treatment is
useful and effective) the use of aspirin for cardiovascular
(including but not specific to stroke) prophylaxis among
persons whose risk is sufficiently high for the benefits to
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of cardiovascular events of 6% to 10%).35 Aspirin can be
useful for prevention of a first stroke among women whose
risk is sufficiently high for the benefits to outweigh the risks
associated with treatment (Class IIa, Level of Evidence B:
The weight of evidence or opinion is in favor of the procedure
or treatment). In summary, the weight of evidence from the
current guidelines state that all patients with significant
carotid artery or peripheral arterial disease should be pre-
scribed aspirin as part of their medical therapy.
ROLE OF ANTIPLATELET THERAPY IN
SECONDARY PREVENTION OF STROKE
Aspirin monotherapy. Follow-up of patients with
TIA or stroke has lasted no longer than three to five years to
determine the incidence of recurrent stroke, myocardial
infarction, and vascular death in modern clinical trials. In
one series, the five-year cumulative risk of recurrent stroke
was 22.5%. Major determinants of recurrence were ad-
vanced age, hemorrhagic stroke, and diabetes mellitus.36 In
cohorts from clinical trials, the annual risk of vascular events
ranged from 4 to 11%.37,38 The corresponding estimate for
population-based studies is 9% per year.39 Follow-up was
complete in 2447 (99%) patients. After a mean follow-up of
10.1 years, 1489 (60%) patients had died and 1336 (54%)
had had at least one vascular event.40 In patients who have
had a previous stroke, there is a significant risk of recurrent
stroke.
Aspirin remains the cornerstone of antiplatelet therapy
for secondary stroke prevention with a 15% to 25% reduc-
tion in risk of recurrent stroke.41,42 The Antithrombotic
Trialists’ Collaborationmeta-analysis indicated that high-dose
aspirin (500-1500 mg/day) was no more effective but was
associated with more gastrointestinal side-effects than me-
dium (160-325 mg/day) or lower (30-150 mg) doses.33
Clopidogrel monotherapy. The Clopidogrel versus
Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial
compared clopidogrel (75mg/day) vs. aspirin (325mg/day)
in reducing the risk of ischemic stroke, myocardial infarction,
or death among 19,185 patients with symptomatic vascular
disease, including recent ischemic stroke.43 Overall, clopi-
dogrel was associated with an 8.7% relative risk reduction
(RRR) for ischemic stroke, myocardial infarction, or death
compared with aspirin (P  .043). However, for the 6431
patients enrolled in CAPRIE due to stroke, the benefit of
clopidogrel over aspirinwas not statistically significant (annual
event rate, 7.15% vs. 7.71%; P .26). It should be noted that
in this post-hoc analysis there was a higher rate of severe
gastrointestinal hemorrhage observed in the aspirin group
when comparedwith the clopidogrel group (0.71% vs. 0.49%;
P .05).
Clopidogrel plus aspirin. Combination therapy with
clopidogrel plus aspirin (75 mg) was compared with clopi-
dogrel monotherapy in the Management of Atherothrom-
bosis with Clopidogrel in High-risk Patients (MATCH)
trial for secondary stroke prevention.44 For the primary
end-point of ischemic stroke, myocardial infarction, or
cardiovascular death, there was no significant benefit of thecombination over monotherapy (15.7% vs. 16.7% respec-
tively, P  NS). In addition, combination therapy was
associated with a twofold increase in risk of major bleeding
(2% vs. 1%; P  .001) and threefold increased risk of
life-threateningbleeding (3% vs. 1%;P .001). This study did
not include an aspirin monotherapy group and therefore
provided no additional information over CAPRIE as to the
advantage of clopidogrel over aspirin.
Of the 12,153 patients studied in the Clopidogrel for
High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance (CHARISMA) trial compar-
ing clopidogrel plus aspirin (75-162 mg/day) vs. aspirin
alone, there were 4,320 patients enrolled for secondary
stroke prevention.45 Overall, the combination regimen did
not reduce stroke risk after a median follow-up of 28
months compared with aspirin alone. However, the rate of
severe bleeding was higher with combination therapy (1.7%
vs. 1.3%; P  .09). A recent post hoc analysis of data from
the CHARISMA trial indicated that daily aspirin doses of
100 mg or greater are not associated with clear benefit and
may cause harm compared with lower doses (75-81mg/d).
The rate of severe or life-threatening bleeding was also
lowest in patients receiving the lowest baseline doses of
aspirin. The overall results suggested that daily aspirin doses
no greater than 81 mg optimize efficacy as well as safety in
patients receiving aspirin for long-term primary and sec-
ondary cardiovascular prevention.46
Aspirin plus extended release dipyridamole (ER-
DP). In a meta-analysis of 25 trials involving 10,404 pa-
tients, aspirin plus dipyridamole was associated with an
additional reduction of 6% in the incidence of stroke com-
pared with aspirin alone (11.8% vs. 12.4%, respectively).33
It should be noted that the largest trials with the largest
effects used an extended release preparation of dipyridi-
mole. The second European Stroke Prevention Study
(ESPS-2) evaluated the efficacy of aspirin plus extended-
release dipyridamole (ER-DP) in prevention of recurrent
stroke.47 The study demonstrated a reduction in risk of
stroke by 18.1% with aspirin mono-therapy (P  .013),
16.3% with ER-DP mono-therapy (P  .04), and 37.0%
with aspirin plus ER-DP (P  .001) compared with pla-
cebo. Aspirin plus ER-DP was twice as effective in stroke
prevention as either drug alone (23% RRR vs. aspirin).
Bleeding complications were similar between combination
therapy (8.7%) and aspirin monotherapy (8.2%). Post hoc
analysis of ESPS-2 showed that aspirin plus ER-DP was
more effective than aspirin alone in preventing stroke
among higher risk patients.48
The aspirin plus dipyridamole versus aspirin alone after
cerebral ischaemia of arterial origin (ESPRIT) study evalu-
ated aspirin plus ER-DP and ER-DP monotherapy twice
daily within six months after TIA or minor stroke.49 At
mean follow-up of 3.5 years, primary outcome events
(composite of death from all vascular causes, non-fatal
stroke, non-fatal myocardial infarction, or major bleeding
complication) occurred in 173 (13%) patients on aspirin
and dipyridamole and in 216 (16%) on aspirin alone (haz-
ard ratio 0.80, 95% CI 0.66 to 0.98; absolute risk reduction
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reduction of 1.0% per year (95% CI 0.1 to 1.8) corresponds
with a number of patients needed to treat with the combi-
nation regimen instead of with monotherapy to prevent a
primary outcome event of 104 (95% CI 55 to 1006) per
year, significant but probably not cost effective. Ischemic
events were less frequent in the combination group than in
the monotherapy group.
Aspirin plus ER-DP vs. clopidogrel. In the recently
reported Prevention Regimen for Effectively Avoiding Sec-
ond Strokes (PRoFESS) Trial, 20,332 patients with a re-
cent (90 days) ischemic stroke were randomized to re-
ceive clopidogrel 75 mg per day or the combination of
aspirin 25 mg and ER-DP 200 mg twice per day.50,51 After
a mean follow-up of 2.5 years, there was no difference in
recurrent stroke (9.0% with aspirin plus ER-DP vs. 8.8% for
clopidogrel; hazard ratio [HR] 1.01; 95% CI 0.92 to 1.11)
or the composite of stroke, myocardial infarction, or vascu-
lar death (13.1% aspirin plus ER-DP vs. 13.1% clopidogrel;
HR 0.99; 95% CI 0.92 to 1.07).50 Although there were
more major hemorrhagic events among the patients taking
aspirin plus ER-DP than in those taking clopidogrel alone
(4.1% vs. 3.6%; P  .06), the overall net risk-benefit, as
measured by recurrent stroke or major hemorrhagic event,
was similar (11.7% for aspirin with ER-DP vs. 11.4% for
clopidogrel; HR 1.03; 95% CI 0.95 to 1.11).50 Thus, for
patients who have had a stroke and and can tolerate
either clopidogrel or aspirin plus ER-DP, there is no
need to alter their regimen.
SECONDARY STROKE PREVENTION
GUIDELINES
The current guidelines52,53 have recently been updated
based on data from the CHARISMA45 and ESPRIT49
studies, with new recommendations outlined for patients
with noncardioembolic ischemic stroke or TIA.54 Aspirin
(50-325 mg/d) monotherapy, the combination of aspirin
and extended-release dipyridamole, and clopidogrel mono-
therapy are all acceptable options for initial therapy (Class I,
Level of Evidence A) in patients with noncardioembolic
ischemic stroke or TIA. The combination of aspirin and
extended-release dipyridamole is recommended over aspi-
rin alone (Class I, Level of Evidence B). For patients allergic
to aspirin, clopidogrel is a reasonable alternative (Class IIa,
Level of Evidence B). The addition of aspirin to clopidogrel
increases the risk of hemorrhage. Combination therapy of
aspirin and clopidogrel is not routinely recommended for
ischemic stroke or TIA patients unless they have a specific
indication for this therapy (ie, coronary stent or acute
coronary syndrome) (Class III).
ANTIPLATELET THERAPY AT THE TIME OF
CAROTID REVASCULARIZATION
Role of antiplatelet therapy in carotid endarter-
ectomy. Postoperative surgical site thrombosis following
carotid endarterectomy (CEA) remains a significant prob-
lem in 2% to 3% of patients.55 This may be preceded by
embolization, which can be detected by transcranial Dopp-ler (TCD) high intensity transient signals (HITS) repre-
senting platelet microemboli.56
At the time of CEA, platelets are activated and adhere
to the site of CEA. Platelet deposition is significantly re-
duced in patients receiving preoperative platelet inhibi-
tors.57 Patients receiving preoperative aspirin had fewer
postoperative strokes (P  .001) and showed a trend
toward reducedmortality (P .11) in a randomized trial.58
A longer-term follow-up study (5.5 years) in CEA patients
confirmed the survival benefit of indefinite platelet inhibi-
tion with aspirin (P  .013).59
Intraoperative dextran has been advocated by some to
reduce the risk of postoperative stroke. Randomized and
observational studies have shown that dextran significantly
reduces cerebral embolic signals detected by TCD,60,61
which have been shown to correlate with cerebral infarc-
tion.62 Naylor et al60 reported a reduction in stroke from
4% to 0.2% with the use of dextran intraprocedurally.
Lennard et al61 began dextran infusions following CEA
when patients had more than 25 HITS detected in any
10-minute period by TCD. The embolic signals of all
patients were abolished when dextran was started. How-
ever, effects of dextran on platelets and the coagulation
cascade make heparin reversal especially important to re-
duce bleeding complications, most notably postoperative
cervical incisional hematoma formation.
A randomized trial of combined platelet inhibition with
aspirin plus clopidogrel versus aspirin alone in patients
undergoing CEA showed significant reduction in operative
and postoperative cerebral emboli as measured by TCD
among those patients receiving combination antiplatelet
therapy.63 There was a 10-fold reduction in the relative risk
of patients having greater than 20 emboli during the post-
operative period (P  .01). Patients who developed high
numbers of emboli in the first one to two hours postoper-
atively, and were therefore, by definition, at higher risk
from stroke,64-67 had platelets that showed a strong re-
sponse to ADP preoperatively despite the use of a standard
150 mg dose of aspirin in all the patients.68 However,
patients receiving aspirin plus clopidogrel had an increased
wound closure time (P .04), which is an indirect marker of
hemostasis. The duration of postoperative combined platelet
inhibition depends on other patient co-morbidities.
To date, clopidogrel therapy has been used infre-
quently in patients undergoing CEA. Unlike patients un-
dergoing carotid artery stenting, in which the percutaneous
approach allows a maximal loading dose of clopidogrel
(300 mg or 600 mg) with minimal risk of bleeding during
the procedure, the risk of bleeding is greater in patients
undergoing open surgery.
Role of antiplatelet therapy in carotid stenting.
Intimal injury of the internal carotid artery during percuta-
neous interventions releases procoagulant tissue factor and
exposes collagen and other platelet-adhesive proteins in the
subendothelium, thereby triggering formation of a platelet-
rich thrombus that seals the site of injury. The extent of
platelet deposition and thrombus formation is dependent
on the degree of vessel wall injury and local shear forces. In
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artery intervention is indicative of increased platelet reac-
tivity to ADP and increased systemic inflammation.69,70
The subsequent healing process involves intense cellular
(monocyte/macrophage) infiltration of the thrombus
along with smooth muscle cell migration and proliferation
at the site of injury, resulting in gradual resorption of the
thrombus and replacement with neointimal tissue. An ex-
cessive healing process, neointimal hyperplasia, leading to
in-stent restenosis, is an important late (typically 30 days
after stent placement) sequela of stenting.
The safety of dual antiplatelet in the context of carotid
artery stenosis has already been demonstrated in the Clopi-
dogrel and Aspirin for the Reduction of Emboli in Symp-
tomatic carotid Stenosis (CARESS) study, conducted in
108 symptomatic patients. This study found that treatment
with clopidogrel (300 mg loading dose on day 1, 75 mg
daily thereafter) and aspirin (75 mg daily) reduced the
incidence of silent cerebral microemboli present on TCD
by 25% after one day and by 37% after seven days of
treatment compared with aspirin alone. Furthermore, dual
antiplatelet therapy did not result in an increase in life-
threatening intracranial or major bleeding events.71
Dual antiplatelet therapy has also shown to be associated
with a low rate of ischemic events in a single-center carotid
stent registry study, which included 162 patients with symp-
tomatic (70% stenosis) or asymptomatic (80% stenosis)
carotid artery stenosis who were not appropriate candidates
for carotid endarterectomy.72 The overall 30-day rate of
ischemic events (death, stroke, TIA, myocardial infarction)
was 5.6% in patients who received clopidogrel or ticlopi-
dine plus aspirin. A significant number of patients also
received periprocedural glycoprotein (GP) IIb/IIIa inhib-
itor therapy. No case of stent thrombosis was reported in
patients who received clopidogrel or ticlopidine plus aspi-
rin, but one of five patients who did not receive an ADP
antagonist did develop in-stent thrombosis. Incidentally,
the 30-day rate of ischemic events was much higher in
patients who received ticlopidine than those who received
clopidogrel (13% vs 4.3%; odds ratio, 5.77; 95% CI 1.45 to
22.91). Dual antiplatelet therapy did not appear to increase
the incidence of intracranial hemorrhage. Admittedly, this
observation is limited by small sample size.
The use of parenteral GPIIb/IIIa inhibitors along with
aspirin and an ADP receptor antagonist has been shown to
be associated with a low risk for ischemic complications
during carotid stenting and with a negligible risk of stent
thrombosis during follow-up. Kapadia et al recruited 151
patients deemed to be at high surgical risk, of which 128
received the GPIIb/IIIa inhibitor abciximab 12 hours
before stenting.73 All patients subsequently received aspirin
and either clopidogrel or ticlopidine after the stenting
procedure. The procedural event rate (all events occurring
up to hospital discharge) was lower in the abciximab-
treated group (1.6%; 1 minor stroke and 1 retinal infarc-
tion) compared with the control group (8%; 1 major stroke
and 1 neurological death). Furthermore, the number of
new periprocedural events occurring in the first 30 daysafter hospital discharge was lower in the abciximab-treated
group than the control group (8% versus 4.5%).
Other studies have described cases of intracerebral
hemorrhage in carotid stent patients who received a
GPIIb/IIIa inhibitor.74,75 Kopp et al randomized patients
with cerebrovascular disease to either standard antithrom-
botic therapy (n 30) comprising clopidogrel, aspirin, and
heparin, or adjunct bolus and 12-hour infusion of abcix-
imab (n  20) before CAS. A third cohort of patients was
treated with carotid stent and distal embolic filter protec-
tion (n  30). Adjunctive abciximab did not significantly
reduce the incidence of periprocedural ischemic events
(10% vs 23%; P  .2) or the number of ischemic lesions
detected by diffusion-weightedMRI (30% vs 47%; P .17)
compared with standard antithrombotic therapy.76 How-
ever, both of these factors were significantly reduced with
embolic protection (P  .023) compared with standard
antithrombotic therapy. Nevertheless, TIAs occurred less
frequently with abciximab (P  .05) compared with stan-
dard antithrombotic therapy.
A retrospective review of 550 patients who underwent
carotid angioplasty and stent placement demonstrated that
combination therapy with GPIIb/IIIa inhibitors and hep-
arin significantly increased the 30-day incidence of the
composite end point of all stroke and neurological death
compared with heparin alone (6.6% versus 2.4%; P 
.04).77 However, this was at the expense of an increased
number of hemorrhage events in the GPIIb/IIIa inhibitors
plus heparin group. Interestingly, Timaran et al recently
reported a six-fold increased risk of intracranial hemorrhage
(ICH) in patients undergoing carotid stenting as opposed
to carotid endarterectomy.78 This retrospective study using
theNationwide Inpatient Sample analyzed 135,903 carotid
revascularizations performed in 2005. The vast majority of
patients underwent CEA (90.4%), whereas CAS was per-
formed in 13,093 (9.6%) patients. ICH occurred in 19
patients (0.15%) after CAS and in 20 patients (0.016%)
after CEA (P  .001). In-hospital mortality was 12.5%
among patients developing ICH (P  .001).
Most centers currently administer dual antiplatelet
therapy for up to four weeks after carotid stent placement to
protect against subacute stent thrombosis. Prolonged dual
antiplatelet therapy may also reduce major ischemic events
in patients after carotid stenting but the data for this has
been mainly extracted form the coronary artery literature.
The Clopidogrel in Unstable angina to prevent Recurrent
Events (CURE) trial enrolled 12,562 patients with unsta-
ble angina or non–ST-segment elevation myocardial infarc-
tion (NSTEMI). This study demonstrated that treatment
with clopidogrel plus aspirin for up to 12 months following
percutaneous coronary intervention (PCI) reduced the rel-
ative risk of the composite of cardiovascular death, stroke,
or myocardial infarction by 20% and the absolute risk by
2.1% compared with aspirin alone (P  .001).79 In addi-
tion, the Clopidogrel for the Reduction of Events during
Observation (CREDO) study, which enrolled 2116 patients
after PCI, found that there was a 26.9% relative reduction in
the combined risk of death, myocardial infarction, or stroke
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year compared with aspirin alone (P .02).80
It must be stated that the optimal dual antiplatelet
regimen for carotid artery stenting has yet to be defined.
Kramer and colleagues have performed an analysis of 38
high risk patients that underwent CAS using combination
of ASA plus ER-DP. There were no procedure related
deaths, stroke, or transient ischemic attacks noted at 24
hours and at 30 days.81 ASA plus ER-DP has previously
shown superiority in reducing event rates in patients with
acute ischemic neurovascular syndromes with few side ef-
fects.47 A head-to-head prospective randomized clinical
trial is warranted to provide the optimal dual antiplatelet
combination.
FUTURE DIRECTIONS
Cilostazol. Cilostazol is a phosphodiesterase type III
inhibitor that possesses both antiplatelet and vasodilatory
effects. Although cilostazol is approved in theUnited States
for treatment of intermittent claudication associated with
peripheral artery disease (PAD), its efficacy in secondary
stroke prevention related to carotid artery stenosis remains
uncertain. This was evaluated in the Cilostazol Stroke
Prevention Study, which randomized 1095 Japanese pa-
tients with recent stroke or TIA to treatment with cilostazol
or placebo. Cilostazol reduced the incidence of secondary
stroke by 41.7% compared with placebo (P  .015). The
greatest risk reduction (43.4%) was among patients en-
rolled after lacunar stroke.82 These clinical benefits were
not associated with adverse events relative to placebo.
However, despite the magnitude of the observed risk re-
duction, the lack of an active comparator arm with aspirin
makes it difficult to compare the efficacy of cilostazol to
that of standard of care.83
Because phosphodiesterase III inhibitors have been
Table. Antiplatelet agents for primary and secondary strok
Indication Agent
Primary prevention Aspirin
or
Clopidogrel
Secondary prevention Aspirin
or
Aspirin  Dipyridimole
or
Clopidogrel
Carotid artery stenting
Pre-procedure Aspirin  Clopidogrel
Post-procedure Aspirin  Clopidogrel
Maintenance Aspirin
Carotid endarterectomy
Aspirin
or
Aspirin  Clopidogrel
COX, Cycloxygenase; ADP, adenosine diphosphatase.shown to cause decreased survival in patients with signifi-cant congestive heart failure, cilostazol is contraindicated in
patients with any degree of congestive heart failure.84 The
Cilostazol in Stroke Prevention-2 study is ongoing to de-
termine the efficacy and safety of cilostazol compared with
aspirin in secondary stroke prevention. Recent studies have
demonstrated benefit of cilostazol in preventing restenosis
and need for repeat revascularization following endovascu-
lar treatment in both the coronary and peripheral circula-
tions.85,86 The effect of cilostazol after percutaneous or
surgical carotid artery revascularization is not known.
CONCLUSIONS
Primary and secondary prevention of stroke is an im-
portant goal for all physicians who care for patients at risk of
this potentially devastating event. Stroke related to ex-
tracranial carotid artery disease represents a serious mani-
festation of atherosclerosis among the ever aging popula-
tion. Appropriate use of antiplatelet agents (Table) in this
specific patient cohort, alone or in conjunction with percu-
taneous or surgical revascularization, is an important ther-
apeutic strategy to prevent stroke.
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